BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Koya Y, Shibata M, Shinohara N, Nebuya S, Oe S, Honma Y, Senju M, Sato N, Harada M. Secondary sclerosing cholangitis with hemobilia induced by pembrolizumab: Case report and review of published work. Hepatol Res. 2019;49:950-956. [PMID: 30861263 DOI: 10.1111/hepr.13329] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Hsu C, Marshall JL, He AR. Workup and Management of Immune-Mediated Hepatobiliary Pancreatic Toxicities That Develop During Immune Checkpoint Inhibitor Treatment. Oncologist. 2020;25:105-111. [PMID: 32043797 DOI: 10.1634/theoncologist.2018-0162] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
2 Hori H, Fujita K, Nishio A, Nishijima M, Inaba M, Anami T, Matsui S, Kitamura Y, Matsuoka R, Watanabe A. Pembrolizumab-related cholangitis with multiple fatal liver abscesses after endoscopic biliary drainage: a case report and review of the literature. Clin J Gastroenterol 2022. [PMID: 35072901 DOI: 10.1007/s12328-022-01593-w] [Reference Citation Analysis]
3 Talbot S, MacLaren V, Lafferty H. Sclerosing cholangitis in a patient treated with nivolumab. BMJ Case Rep 2021;14:e241700. [PMID: 34049893 DOI: 10.1136/bcr-2021-241700] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ooi R, Tobino K, Sakabe M, Kawabata T, Hiramatsu Y, Sueyasu T, Yoshimine K. A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis. Respir Med Case Rep 2020;31:101197. [PMID: 32944497 DOI: 10.1016/j.rmcr.2020.101197] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Nakano R, Shiomi H, Fujiwara A, Yoshihara K, Yoshioka R, Kawata S, Ota S, Yuri Y, Takashima T, Aizawa N, Ikeda N, Nishimura T, Enomoto H, Iijima H. Clinical Characteristics of ICI-Related Pancreatitis and Cholangitis Including Radiographic and Endoscopic Findings. Healthcare 2022;10:763. [DOI: 10.3390/healthcare10050763] [Reference Citation Analysis]
6 Sato K, Hayashi M, Abe K, Fujita M, Takahashi A, Ohira H. Pembrolizumab-induced sclerosing cholangitis in a lung adenocarcinoma patient with a remarkable response to chemotherapy: a case report. Clin J Gastroenterol 2020;13:1310-4. [PMID: 32643124 DOI: 10.1007/s12328-020-01178-5] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Hirasawa Y, Yoshimura K, Matsui H, Kubota Y, Ishida H, Arai J, Sakaki M, Oguro N, Shida M, Taniguchi M, Hamada K, Ariizumi H, Ishiguro T, Ohkuma R, Sambe T, Horiike A, Imamura CK, Shiozawa E, Wada S, Tsurutani J, Iwamoto S, Uchida N, Kiuchi Y, Tate G, Kobayashi S, Tsunoda T. A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy. Medicine (Baltimore) 2021;100:e25774. [PMID: 34114983 DOI: 10.1097/MD.0000000000025774] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Cataldi M, Manco F, Tarantino G. Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate Story. Int J Mol Sci 2021;22:12947. [PMID: 34884762 DOI: 10.3390/ijms222312947] [Reference Citation Analysis]
9 Vitale G, Lamberti G, Comito F, Di Nunno V, Massari F, Morelli MC, Ardizzoni A, Gelsomino F. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience. Expert Opin Biol Ther 2020;20:1047-59. [PMID: 32425081 DOI: 10.1080/14712598.2020.1762562] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Sawada K, Hayashi H, Nakajima S, Hasebe T, Fujiya M, Okumura T. Non‐alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor. Journal of Gastroenterology and Hepatology 2020;35:1042-8. [DOI: 10.1111/jgh.14889] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
11 Honma Y, Shibata M, Gohda T, Matsumiya H, Kumamoto K, Miyama A, Morino K, Koya Y, Taira A, Shinohara S, Hayashi T, Kusanaga M, Oe S, Miyagawa K, Abe S, Tanaka F, Harada M. Rapid Progression of Liver Fibrosis Induced by Acute Liver Injury Due to Immune-related Adverse Events of Atezolizumab. Intern Med 2021;60:1847-53. [PMID: 33456046 DOI: 10.2169/internalmedicine.6535-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
12 Zhang Z, Xu L, Qin N, Zhang J, Xiang Q, Liu Q, Cheng Y, Bai Y, Liu Q, Liu Y, Duan X, Cui Y. Case report: Secondary sclerosing cholangitis induced by lapatinib and vinorelbine in a metastasis breast cancer patient. Thorac Cancer 2021;12:1912-6. [PMID: 33957015 DOI: 10.1111/1759-7714.13986] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Onoyama T, Takeda Y, Yamashita T, Hamamoto W, Sakamoto Y, Koda H, Kawata S, Matsumoto K, Isomoto H. Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review. World J Gastroenterol 2020; 26(3): 353-365 [PMID: 31988594 DOI: 10.3748/wjg.v26.i3.353] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]